Anatomical Therapeutic Chemical • L04AC17 • tildrakizumab

A Alimentary tract and metabolism

B Blood and blood forming organs

C Cardiovascular system

D Dermatologicals

G Genito urinary system and sex hormones

H Systemic hormonal preparations, excluding sex hormones and insulins

J Antiinfectives for systemic use

L Antineoplastic and immunomodulating agents

L01 Antineoplastic agents

L02 Endocrine therapy

L03 Immunostimulants

L04 Immunosuppressants

L04A Immunosuppressants

L04AA Selective immunosuppressants

L04AB Tumor necrosis factor alpha (tnf-alpha) inhibitors

L04AC Interleukin inhibitors

L04AC02 basiliximab

L04AC03 anakinra

L04AC05 ustekinumab

L04AC07 tocilizumab

L04AC08 canakinumab

L04AC10 secukinumab

L04AC11 siltuximab

L04AC13 ixekizumab

L04AC16 guselkumab

L04AC17 tildrakizumab

L04AC18 risankizumab

L04AC19 satralizumab

L04AC21 bimekizumab

L04AC22 spesolimab

L04AC24 mirikizumab

L04AD Calcineurin inhibitors

L04AE Sphingosine-1-phosphate (S1P) receptor modulators

L04AF Janus-associated kinase (JAK) inhibitors

L04AG Monoclonal antibodies

L04AH Mammalian target of rapamycin (mTOR) kinase inhibitors

L04AJ Complement inhibitors

L04AK Dihydroorotate dehydrogenase (DHODH) inhibitors

L04AX Other immunosuppressants

M Musculo-skeletal system

N Nervous system

P Antiparasitic products, insecticides and repellents

R Respiratory system

S Sensory organs

V Various